BK0042 Chemical Pharmaceuticals
- 794.152
- +0.682+0.09%
Hengrui diet pills went overseas for 6 billion US dollars, and this time they are no longer making wedding gowns for others | Insight Research
Through an innovative transaction structure, Hengrui uses minimal risk to obtain the highest potential overseas returns, while providing shareholders with more stable returns.
2024 Financial Report | After breaking through 40 billion dollars in revenue, how can Huadong Pharmaceutical face the challenge of “deceleration”
Big dividends
Backed by Huadong Pharmaceutical, Quanxin Biotech's All in the Field of Self-Immunity | Insight Research
Through a hearing on the Hong Kong Stock Exchange, the secondary market also welcomed a major free player.
Teva Pharmaceutical Investments Singapore, A Subsidiary Of Teva Pharmaceutical Industries And Jiangsu Nhwa Pharmaceutical Formed A Partnership To Market And Distribute Teva's Austedo (Deutetrabenazine) For Neurodegenerative And Movement Disorders
Teva Pharmaceutical Investments Singapore, A Subsidiary Of Teva Pharmaceutical Industries And Jiangsu Nhwa Pharmaceutical Formed A Partnership To Market And Distribute Teva's Austedo (Deutetrabenazine
Evotec's Partner Zhejiang Jingxin Pharmaceutical Secures Approval From Chinese Medical Authority For Evotec's Insomnia Drug, EVT201
Evotec is entitled to receive double-digit royalties of net sales as well as milestones based on commercial success and further sub-licensing.
The net profit of Harbin Pharmaceutical Co., Ltd. has more than tripled in the three quarters: driven by the recovery of health products, sustainability is yet to be tested
Back to normal
People who lose weight aren't in a hurry; are pharmaceutical companies in a hurry? The chairman of Borui Pharmaceutical claims to have “tried drugs on his own” to lose 30 pounds or is mired in controversy
Insane.
GLP-1 drugs have become a stock price code: Why did Changshan Pharmaceutical, which has no weight loss tests and no disclosure of efficacy data, take off?
As a rising star in the weight loss industry, glucosane-like peptide-1 receptor (“GLP-1”) drugs are stirring up the stock prices of pharmaceutical companies that have been dormant for a long time. On September 26, Changshan Pharmaceutical (300255.SZ) issued the “Notice on Abnormal Stock Trading Fluctuations”, which emphasized that the clinical trial indications of the GLP-1 drug albenatide were type 2 diabetes and did not involve obesity indications. “The company has not conducted clinical trials of abenatide for obesity or weight loss. The company has no revenue related to weight loss products.” Changshan Pharmaceutical pointed out. This is the 3rd release by Changshan Pharmaceutical since September about abenatide
Huahai Pharmaceutical's refinancing bets on 100 tons of COVID-19 drugs: disputes over economic benefits still exist
In the context of tightening refinancing, the rationality and necessity of refinancing for A-share companies has received widespread attention from the market. Recently, Huahai Pharmaceutical (600521.SH) updated the refinancing inquiry response materials. Among them, the issue of the rationality of estimating the economic benefits of the production expansion plan attracted the attention of the regulatory authorities. According to the application materials, Huahai Pharmaceutical plans to raise 1,560 billion yuan to invest in the construction of “digital intelligent manufacturing of formulations”, “multi-functional production platform for specialty APIs such as antiviruses” projects, and supplementary liquidity. Among them, the “Multifunctional Production Platform for Antiviral and Other Special APIs” project involves “an annual output of 100 tons
There was still 180 million dollars in the previous round of “financial management”, and what is Minova's intention to sell another 600 million dollars in a fixed increase
The efficiency of capital use is yet to be tested
Shanghai Fosun Pharmaceutical Reports 1H Results
The suspected pollution of Erkang Pharmaceuticals' Cambodian factory was evicted due to a local request and an announcement will be made later
Serious pollution
Ardelyx Announces Acceptance Of New Drug Application For Tenapanor For Hyperphosphatemia In China; Triggers $2M Milestone Payment To Ardelyx Under The Terms Of The License Agreement Between Co And Shanghai Fosun Pharmaceutical Industrial Development Co.
Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, t
The FDA Clears C4 Therapeutics' Investigational New Drug Application For CFT8919 For Non-small Cell Lung Cancer; C4T Expects To Initiate Trials Outside Greater China After Betta Pharmaceuticals Concludes Phase 1 Dose Escalation Study In Greater China
The FDA Clears C4 Therapeutics' Investigational New Drug Application For CFT8919 For Non-small Cell Lung Cancer; C4T Expects To Initiate Trials Outside Greater China After Betta Pharmaceuticals Conclu
Trevena Receives Milestone Payment From Partner in China Jiangsu Nhwa Pharmaceutical
Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced t
InnoCare Pharma Limited Reports FY Results
Disc Medicine Announces Exclusive Licensing Agreement With Mabwell Therapeutics For Novel Anti-TMPRSS6 Monoclonal Antibodies To Modulate Iron Homeostasis; Mabwell To Receive $10M Upfront Payment And Up To $412.5M In Milestones
Disc Medicine Announces Exclusive Licensing Agreement With Mabwell Therapeutics For Novel Anti-TMPRSS6 Monoclonal Antibodies To Modulate Iron Homeostasis; Mabwell To Receive $10M Upfront Payment And U
China's National Medical Products Administration In Late December Met With Several Chinese Drugmakers Including Zhejiang Huahai Pharmaceutical And CSPC Pharmaceutical Group To Discuss Preparations Needed To Make A Generic Version Of Paxlovid
China's National Medical Products Administration In Late December Met With Several Chinese Drugmakers Including Zhejiang Huahai Pharmaceutical And CSPC Pharmaceutical Group To Discuss Preparations Nee
INNOVATE Corp's MediBeacon Receives $10M In Amended Agreements With Huadong Medicine
MediBeacon Inc., a portfolio company within the Pansend Life Sciences segment of INNOVATE Corp. (NYSE:VATE), today announced amendments to its commercial partnership with Huadong Medicine Co., Ltd., w
InnoCare Pharma Limited Reports 9M Results